NEW YORK, June 1, 2026, 06:04 EDT
- Werewolf Therapeutics changed hands near $0.45 early Monday, holding close to its 52-week low.
- Director Luke Evnin’s associated entities sold 141,106 shares under a preset trading plan, according to a late Friday SEC filing.
- Werewolf’s review of strategic alternatives is still the main focus after the Jazz deal and debt payment.
Werewolf Therapeutics stock traded near 45 cents Monday morning, holding close to its 52-week low on Nasdaq. Investors watching for updates on the company’s ongoing strategic review. Shares were flat in early trading, putting the company’s market cap near $22 million.
The timing here is important because the most recent company-specific filing before this week wasn’t a trial update—it was an insider sale. A Form 4 filed after the bell Friday showed entities tied to director Luke Evnin dumped a total of 141,106 Werewolf shares between May 27 and May 29, using a Rule 10b5-1 plan, which lets insiders sell stock on a schedule.
Sales hit weighted average prices of $0.48, $0.46 and $0.45 over three sessions, according to the filing. The plan started on March 26, the filing said.
Nasdaq isn’t closing markets on June 1 in 2026, according to the exchange’s posted holiday schedule. The next scheduled U.S. stock market holiday is Juneteenth, June 19. Biotech stocks showed a slightly better tone before the bell, with the SPDR S&P Biotech ETF up around 0.5%. The iShares Nasdaq Biotechnology ETF was flat in premarket trading.
Werewolf hasn’t released a more recent operating update since its May 7 first-quarter report. The company then said it was looking at “strategic options to maximize shareholder value.” CEO Daniel J. Hicklin said Werewolf “continues to explore a range of alternatives,” with Piper Sandler acting as advisor. GlobeNewswire
The ongoing review has turned into the main driver for Werewolf shares. Werewolf said Jazz Pharmaceuticals Ireland picked up exclusive global rights to JZP898, the interferon alpha program it already had licensed from Werewolf. The company also said it finished repaying the K2 HealthVentures loan.
Jazz put up $21 million cash up front, according to a quarterly filing, with another $2 million possibly coming if a license-consent provision is triggered. Werewolf said it used about $31.4 million to pay off its K2 debt.
Werewolf Therapeutics said it held $46.5 million in cash and cash equivalents as of March 31, down from $57.1 million at the end of 2025. First-quarter net loss came in at $13.5 million, compared to $18.1 million in the same period last year. The company said lower R&D spending helped cut losses.
But the risk is clear. Werewolf said in its 10-Q that it doesn’t have enough cash to fund its current operating plan for at least the next 12 months from the filing date. The company said these conditions bring “substantial doubt” about staying a going concern, meaning it can’t keep running without more cash. Werewolf Therapeutics, Inc.
The competitive field isn’t getting easier. CytomX Therapeutics calls itself a leader in masked, conditionally activated biologics. Xilio Therapeutics has its own tumor-activated immuno-oncology pipeline meant to trigger only inside cancer cells. That leaves Werewolf’s last INDUKINE and INDUCER programs packed in with other oncology biotechs, where catching a partner often counts as much as any index gain.
HOWL holders are looking for an answer soon on whether the strategic process will turn up a deal that puts a price on the leftover assets. If not, the stock may keep behaving like a cash and financing play, not a pipeline name.
